$INVA News

Last published 1w ago

1w agoINVAInnoviva, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
3w agoINVAInnoviva Specialty Therapeutics to Present Data Across Infectious Disease Portfolio at IDWeek 2026Business WirePresentations span ceftobiprole and zoliflodacin, highlighting post-approval evidence generation across antimicrobial-resistant and difficult-to-treat infections Innoviva Specialty Therapeutics (IST), a subsidiary of
2mo agoINVAInnoviva to Participate in Upcoming Investor ConferencesBusiness WireInnoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as
3mo agoINVAInnoviva Specialty Therapeutics’ Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product AwardBusiness WireInnoviva Specialty Therapeutics (IST), a subsidiary of Innoviva, Inc. (NASDAQ:INVA), announced today that three of the company’s infectious disease therapies, XACDURO® (sulbactam/durlobactam for injection), ZEVTERA®
3mo agoINVAInnoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company ProgressBusiness WireIST achieved U.S. net product sales of $36.6 million in the second quarter, representing 26% year-over-year growth Royalties portfolio generated $59.8 million in second quarter revenue Launch of wholly-owned
4mo agoINVANortiva Bio Launches to Develop Long-Acting Oral MedicinesBusiness WireCompany is advancing its proprietary LYNX™ drug delivery platform to develop oral therapies that last for up to a month, including a monthly oral contraceptive Company seeks pipeline expansion via industry
4mo agoINVAInnoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy's for XACDURO® in Select International MarketsBusiness WireAgreement expands access to XACDURO® for patients with serious Acinetobacter baumannii-calcoaceticus complex (Acinetobacter) infections across South and Central America, the Caribbean, Russia and CIS countries
5mo agoINVAInnoviva to Participate in Upcoming Investor ConferencesBusiness WireInnoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty
6mo agoINVAInnoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company ProgressBusiness WireGenerated $58.6 million in revenue from resilient royalties portfolio Achieved IST U.S. net product sales of $34.2 million for the first quarter, representing 29% year-over-year growth Significant value created
8mo agoINVAInnoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceBusiness WireInnoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics
11mo agoINVAU.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and AdolescentsBusiness WireFDA approval was based on results from the largest Phase 3 clinical trial ever conducted for a new treatment against Neisseria gonorrhoeae infection in regions with a high prevalence of gonorrhea across five
11mo agoINVAInnoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital GonorrheaBusiness WirePhase 3 findings show oral zoliflodacin to be non-inferior to the combination of ceftriaxone and azithromycin for the treatment of uncomplicated urogenital gonorrhea. Positive study results are a significant
11mo agoINVAInnoviva to Participate in the 37th Annual Piper Sandler Healthcare ConferenceBusiness WireInnoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics
1y agoINVAAntheia Appoints Eric d'Esparbes as Chief Financial OfficerPR NewswireAntheia, the pharmaceutical ingredient manufacturer transforming essential medicine supply chains, today announced the appointment of Eric d'Esparbes ...
1y agoINVAInnoviva Specialty Therapeutics Announces Oral Presentation Featuring New Analyses from the Zoliflodacin Pivotal Phase 3 Trial at IDWeek 2025Business WireZoliflodacin, an investigational single-dose oral antibiotic for uncomplicated gonorrhea, to be featured in oral presentation with key subset analyses from pivotal global Phase 3 trial Innoviva Specialty Therapeutics,
1y agoINVAInnoviva Specialty Therapeutics to Deliver Six Presentations from its Infectious Diseases and Critical Care Portfolio at IDWeek 2025Business WireHighlights include an oral presentation of a subset analysis from the Phase 3 clinical trial of zoliflodacin, an investigational single-dose oral treatment for uncomplicated gonorrhea due to Neisseria
1y agoINVAInnoviva, Inc. (INVA) Presents At Citi's Biopharma Back To School Conference TranscriptEarnings Call Transcripts
1y agoINVAInnoviva to Participate in Upcoming Investor ConferencesBusiness WireInnoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics
1y agoINVAInnoviva Specialty Therapeutics' Antimicrobial Therapies ZEVTERA® and XACDURO® Nominated for the 2025 Prix Galien USA Best Pharmaceutical Product AwardBusiness WireInnoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (NASDAQ:INVA), announced today that two of the company's infectious disease therapies, ZEVTERA® (ceftobiprole medocaril sodium for injection) and
1y agoINVAInnoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company ProgressBusiness WireStrong royalties portfolio performance with $67.3 million in revenue IST achieved U.S. net product sales of $29.0 million, reflecting 54% year-over-year growth ZEVTERA (ceftobiprole medocaril sodium, for injection)
1y agoINVAFDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025Business WireFDA is expected to notify Innoviva Specialty Therapeutics regarding its decision to conduct an Advisory Committee Meeting in the Day 74 letter If approved, zoliflodacin would be the first new antibiotic for treating
1y agoINVAInnoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in AdultsBusiness WireIn laboratory studies, zoliflodacin has been shown to be active against Neisseria gonorrhoeae including multidrug-resistant strains. If approved, zoliflodacin could become the first new antibiotic treatment for
1y agoINVAInnoviva to Participate in Upcoming Investor ConferencesBusiness WireInnoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics
1y agoINVAZEVTERA® (ceftobiprole), an Advanced-Generation Cephalosporin Antibiotic Now Commercially Available in the U.S. to Treat Three Types of Bacterial InfectionsBusiness WireZEVTERA is the first and only U.S. Food and Drug Administration-approved cephalosporin indicated to treat Staphylococcus aureus bacteremia (SAB), including right-sided endocarditis, caused by the methicillin-resistant
1y agoINVABasilea announces commercial availability of antibiotic Zevtera® (ceftobiprole) in the United StatesGlobeNewswireAllschwil, Switzerland, May 20, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal
1y agoINVAInnoviva Reports First Quarter 2025 Financial Results; Highlights Recent Company ProgressBusiness WireCore royalty platform maintained strong performance, generating $61.3 million in revenue Innoviva Specialty Therapeutics achieved U.S. net product sales of $26.4 million for the first quarter, reflecting 52%
1y agoARMP INVAArmata Pharmaceuticals Announces $10 Million Secured Credit Agreement with InnovivaPR NewswireArmata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of...
1y agoINVAInnoviva to Participate in the Barclays 27th Annual Global Healthcare ConferenceBusiness WireInnoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics
1y agoINVAInnoviva Reports Fourth Quarter and Full Year 2024 Financial Results; Highlights Recent Company ProgressBusiness WireCore royalty platform continues to deliver with GSK royalties of $66.0 million for the fourth quarter and $255.6 million for the full year Innoviva Specialty Therapeutics achieved U.S. net product sales of $24.9
1y agoINVAInnoviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceBusiness WireInnoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics
1y agoINVAInnoviva Specialty Therapeutics Signs Exclusive Distribution and Licensing Agreement to Acquire U.S. Marketing Rights for Zevtera® (ceftobiprole)Business WireInnoviva Specialty Therapeutics, Inc., ("IST") a subsidiary of Innoviva, Inc. (NASDAQ:INVA), today announced it has entered into an exclusive distribution and license agreement with Basilea Pharmaceutica Ltd, Allschwil
1y agoINVABasilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United StatesGlobeNewswireAd hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, December 16, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs
1y agoINVAInnoviva to Participate in the Citi 2024 Global Healthcare ConferenceBusiness WireInnoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics
1y agoINVAInnoviva to Participate in the UBS Global Healthcare ConferenceBusiness WireInnoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics
2y agoINVAInnoviva Reports Third Quarter 2024 Financial Results; Highlights Recent Company ProgressBusiness WireCore royalty platform continued strong performance, receiving GSK royalties of $60.5 million with 6% year-over-year growth Innoviva Specialty Therapeutics' (IST) marketed portfolio achieved U.S. net product sales of
2y agoINVAInnoviva to Participate in Upcoming Investor ConferencesBusiness WireInnoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics
2y agoINVAInnoviva Reports Second Quarter 2024 Financial Results; Highlights Recent Company ProgressBusiness WireCore royalty platform continued strong performance, receiving GSK royalties of $67.2 million Innoviva Specialty Therapeutics' (IST) marketed portfolio grew 38% year-over-year, achieving net product sales of $21.7
2y agoINVAInnoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceBusiness WireInnoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics
2y agoINVAInnoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company ProgressBusiness WireCore royalty platform on track; receiving GSK royalties of $61.9 million Achieved net product revenues of $19.1 million, representing 66% year-over-year growth driven by launch of XACDURO® and growth of key core
2y agoINVAInnoviva to Participate in the BofA Securities Health Care ConferenceBusiness WireInnoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics
2y agoINVAInnoviva Specialty Therapeutics' Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024Business WireSingle-dose, oral zoliflodacin achieved 90.9% microbiological cure rate, demonstrating statistical non-inferiority compared to current global standard of care Pivotal Phase 3 data to be presented by the Global
2y agoARMP INVAArmata Pharmaceuticals Announces $35 Million Secured Credit Agreement with InnovivaPR NewswireArmata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage...
2y agoINVAInnoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company ProgressBusiness WireCore royalty platform on track; received GSK royalties of $69.6 million for fourth quarter Achieved net product revenues of $19.7 million for the fourth quarter of 2023 representing 35% year on year growth Strong
3y agoARMP INVAInnoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company ProgressBusiness WireReceived GSK royalties of $57.0 million and net product revenues of $13.7 million in the third quarter of 2023 Launched first-in-class therapy XACDURO® for treatment of hospital-acquired bacterial pneumonia and
3y agoINVAPositive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated GonorrheaBusiness WireA Phase 3 study of oral zoliflodacin met the primary endpoint when compared against the combination of injectable ceftriaxone and oral azithromycin, a current international standard of care. Positive top-line study
3y agoINVAInnoviva Specialty Therapeutics Presents New Data on its Critical Care Antibiotic Therapy Portfolio at Infectious Disease Week (IDWeek) 2023Business WireOral presentation highlights new findings about the efficacy of XACDURO® for the treatment of monomicrobial and polymicrobial Acinetobacter baumannii-calcoaceticus infections Researchers share global
3y agoINVAInnoviva to Participate in the Cantor Global Healthcare ConferenceBusiness WireInnoviva, Inc. (NASDAQ:INVA) ("Innoviva"), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will participate in a
3y agoINVAXACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in AdultsBusiness WireXACDURO is a new FDA-approved treatment used to fight against HABP/VABP infections caused by isolates of Acinetobacter baumannii-calcoaceticus complex, which can include those resistant to carbapenems (CRAB). In the
3y agoINVAInnoviva Appoints Stephen Basso as Chief Financial OfficerBusiness WireInnoviva, Inc. (NASDAQ:INVA) ("Innoviva" and "the Company"), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced the appointment of Stephen Basso as its Chief
3y agoARMP INVAArmata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage TherapeuticsPR NewswireSigns new $25 million credit agreement and extension of existing secured convertible credit agreement Appoints world‐renowned healthcare leader Dr. Deborah L. Birx as Chief Executive Officer MARINA DEL REY, Calif., July